The Orphan Drug Designation is a positive regulatory milestone that can enhance the drug development pathway for Lisata Therapeutics by providing benefits such as tax credits, seven years of market exclusivity upon approval, and FDA assistance. This designation often leads to increased investor interest and can positively impact the company's stock price in the short term due to the perceived potential for market exclusivity and the accelerated development process.